Goldman Sachs Maintains Buy on Revance Therapeutics, Lowers Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Chris Shibutani has maintained a 'Buy' rating on Revance Therapeutics (NASDAQ:RVNC), but lowered the price target from $38 to $33.
September 21, 2023 | 8:57 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs has maintained a 'Buy' rating on Revance Therapeutics, but lowered the price target from $38 to $33.
While the 'Buy' rating is maintained, the lowering of the price target could indicate a potential decrease in the short-term value of the stock. However, the impact is not necessarily negative as the 'Buy' rating is still in place, suggesting that the stock is still expected to perform well in the long run.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100